TruAlt Bioenergy Ltd
TruAlt Bioenergy Q2 Results 2026 (FY27): Revenue ₹811.10 Cr, PAT ₹46.03 Cr
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Top 10 Agricultural Food & other Products companies on management guidance
See the sector's top 10 — free with your mobile number.
TruAlt Bioenergy Ltd Q2 FY27 key numbers
- Revenue
- For the 6 months ended 30 Sept 2026, consolidated revenue from operations was ₹ 1,727.51 Cr, a 243% YoY increase from ₹ 418.75 Cr.
As stated in TruAlt Bioenergy Ltd's Q2 FY27 investor presentation · published 23 Oct 2026. Reported figures, not investment advice.
Based on TruAlt Bioenergy Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY 27 consolidated revenue from operations was ₹ 811.10 Cr, a 536% quarter-on-quarter and 668% year-on-year increase from ₹ 104.48 Cr in Q2 FY 26 (Page 34, 38). EBITDA (Q2 FY27): ₹99.08 Cr., up from a loss of ₹11.79 Cr.
From TruAlt Bioenergy Ltd's Q2 FY27 earnings-call transcript · updated 23 Oct 2026.
Revenue & Sales Performance
- Q2 FY 27 consolidated revenue from operations was ₹ 811.10 Cr, a 536% quarter-on-quarter and 668% year-on-year increase from ₹ 104.48 Cr in Q2 FY 26 (Page 34, 38).
- Standalone revenue from operations for Q2 FY 27 was ₹ 802.61 Cr, up 668% YoY from ₹ 104.48 Cr in Q2 FY 26 (Page 38).
- For the 6 months ended 30 Sept 2026, consolidated revenue from operations was ₹ 1,727.51 Cr, a 243% YoY increase from ₹ 418.75 Cr (Page 33).
- Standalone H1 revenue was ₹ 1,418.53 Cr, a 256% YoY increase from ₹ 398.41 Cr (Page 39).
Profitability & Margins
See what TruAlt Bioenergy Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ethanol Business:
- Capacity: 2,000 KLPD installed, including 1,300 KLPD with dual-feed.
- Focus on improving capacity utilization and production alignment.
- CBG Expansion:
- Phase I: Four CBG units, total capital outlay ₹340 crore (₹85 crore/unit).
- Capacity ramp-up: FY27 40%, FY28 85%, FY29 ~90%.
- Feedstock: Press mud and spent wash.
- Total committed capital: ₹180 crore + ₹60 crore equity for three locations.
- Units under construction:
- Unit 2 Mudhol, Karnataka – operational by end Q2 FY27.
- Unit 3 Kerakalmatti, Karnataka – operational by end Q3 FY27.
- Unit 4 Badami, Karnataka – 90% civil, 65% mechanical complete; commissioning targeted Dec 2026.
- Unit 5 Daund, Maharashtra – construction to start post documentation; operational by end Q4 FY27.
- Six additional sites jointly identified with GAIL.
- Sustainable Aviation Fuel (SAF):
- Proposed 100 million litres per annum SAF plant in Andhra Pradesh.
- Development with Honeywell UOP technology.
- Grant sanction: ₹150 crore under PM JI-VAN Yojana.
- Retail Fuel Network:
2 more points from TruAlt Bioenergy Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Agricultural Food & other Products
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what TruAlt Bioenergy Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what TruAlt Bioenergy Ltd said on order book & pipeline — free account, 30 seconds.
TruAlt Bioenergy Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹811 Cr, net profit ₹35 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What TruAlt Bioenergy's management said in earlier quarters
Others in Agricultural Food & other Products this season
- A C J K Exports (Q2 FY27)
1,136 million, up by 70% YoY from Rs. Key results statement takeaways from Amir Chand Jagdish Kumar (Exports) Ltd's Q2 FY27 results statement — and how it ranks
- The Peria Karamalai Tea (Q2 FY27)
68.4 lakhs (~6.5% decline) . Key results statement takeaways from The Peria Karamalai Tea & Produce Company Ltd's Q2 FY27 results statement — and how it ranks a
- Triven.Engg.Ind. (Q2 FY27)
Q2 FY27 Revenue (Net of Excise Duty):** ₹1,731 crores, up 8.4% YoY from ₹1,597 crores in Q2 FY26. Key investor presentation takeaways from Triveni Engineering a
- KRBL (Q2 FY27)
Q2 FY27 consolidated revenue from operations: ₹1,727 crore, up 14% YoY (Page 11). Key investor presentation takeaways from KRBL Ltd's Q2 FY27 investor presentat
Potential multibaggers · Q2 FY27
Potential multibaggers in Agricultural Food & other Products
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
TruAlt Bioenergy Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were TruAlt Bioenergy Ltd Q2 FY27 results?
Q2 FY 27 consolidated revenue from operations was ₹ 811.10 Cr, a 536% quarter-on-quarter and 668% year-on-year increase from ₹ 104.48 Cr in Q2 FY 26 (Page 34, 38). EBITDA (Q2 FY27): ₹99.08 Cr., up from a loss of ₹11.79 Cr.
What is TruAlt Bioenergy Ltd share price analysis?
TruAlt Bioenergy Ltd currently shows a neutral. The stock trades at a P/E of 22.3 with a market cap of ₹3,490 Cr. Investors should review the full earnings analysis for detailed insights.
Is TruAlt Bioenergy Ltd planning capital expenditure?
Ethanol Business: - Capacity: 2,000 KLPD installed, including 1,300 KLPD with dual-feed.
Keep TruAlt Bioenergy Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.